Flaws in the regulatory system are apparent, but how to rectify them remains unclear.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Rights and permissions
About this article
Cite this article
Frantz, S. How to avoid another 'Vioxx'. Nat Rev Drug Discov 4, 5–7 (2005). https://doi.org/10.1038/nrd1629
Issue Date:
DOI: https://doi.org/10.1038/nrd1629
This article is cited by
-
Painkiller verdict shows mistrust of Merck
Nature (2005)
-
Drug safety on trial
EMBO reports (2005)
-
Vioxx may go back on sale after scraping past FDA panel
Nature (2005)
-
Monitoring the safety of licensed medicines
Nature Reviews Drug Discovery (2005)